프레가발린 시장 규모, 점유율, 성장 분석 : 제형별, 용도별, 약제 클래스별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Pregabalin Market size was valued at USD 1.97 Billion in 2024 and is poised to grow from USD 2.05 Billion in 2025 to USD 2.76 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).

The pregabalin market is experiencing significant growth driven by the increasing prevalence of neurological disorders, particularly epilepsy and neuropathic pain among adults. Efforts by market players to enhance access in low-income and underserved regions are also contributing to this expansion. With over 50 million individuals worldwide affected by epilepsy, and a large percentage potentially achieving seizure freedom through proper treatment, the demand for pregabalin remains robust. The adult demographic, particularly those aged 25 to 60, displays the highest incidence of chronic conditions such as neuropathic pain, fibromyalgia, and generalized anxiety disorder, making it the primary consumer segment. Furthermore, significant gaps in treatment availability in low-income countries highlight the need for improved accessibility, thereby further propelling the growth of the pregabalin market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pregabalin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pregabalin Market Segments Analysis

Global Pregabalin Market is segmented by Forms, Application, Drug Class, Distribution Channel, End User and region. Based on Forms, the market is segmented into Oral Capsule, Oral Solution, Oral Tablet and Extended Release. Based on Application, the market is segmented into Epilepsy, Neuropathic Pain, Anxiety Disorder and Others. Based on Drug Class, the market is segmented into Fibromyalgia Agents, Anticonvulsants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pregabalin Market

The growing incidence of neuropathic pain and generalized anxiety disorders is significantly boosting the global demand for pregabalin. Healthcare professionals in both advanced and developing regions are increasingly recommending pregabalin due to its dual therapeutic applications in managing chronic pain and alleviating anxiety symptoms. Furthermore, the inclusion of pregabalin as a first-line treatment option in updated clinical guidelines across various countries is enhancing its utilization in the fields of neurology and psychiatry. This expanding acceptance and application of pregabalin are contributing to its rising prominence in pharmaceutical therapies aimed at improving patient outcomes.

Restraints in the Global Pregabalin Market

The global pregabalin market faces significant challenges due to its classification as a controlled substance in many regions, which restricts its market growth. Concerns over potential abuse and dependency prompt regulatory bodies to enforce stringent prescribing restrictions. These regulations create barriers for adoption, particularly among general care units and outpatient settings, as healthcare providers may hesitate to prescribe pregabalin due to the increased administrative requirements involved. The need for comprehensive record keeping and oversight may further discourage some practitioners from offering it to patients, ultimately hindering its overall penetration in the market and limiting accessibility for those who may benefit from the treatment.

Market Trends of the Global Pregabalin Market

The global pregabalin market is witnessing a notable upward trajectory, driven by heightened demand for effective neuropathic pain relief solutions. As chronic pain disorders, particularly prevalent among the aging population in North America and Europe, continue to rise, healthcare providers and patients alike are increasingly turning to pregabalin for managing conditions like diabetic neuropathy and post-herpetic neuralgia. This surge in demand is prompting pharmaceutical companies to innovate, leading to the introduction of specialized dosage forms and long-acting formulations tailored to meet diverse patient needs. The focus on geriatric patients further emphasizes the industry's commitment to enhancing tolerability and compliance in pain management strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Pregabalin Market Size by Forms & CAGR (2026-2033)

• Market Overview
• Oral Capsule
• Oral Solution
• Oral Tablet
• Extended Release

Global Pregabalin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Fibromyalgia Agents
• Anticonvulsants
• Others

Global Pregabalin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pregabalin Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pregabalin Market Size & CAGR (2026-2033)

• North America (Forms, Application, Drug Class, Distribution Channel, End User)
  • US
  • Canada
• Europe (Forms, Application, Drug Class, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Forms, Application, Drug Class, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Forms, Application, Drug Class, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Forms, Application, Drug Class, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals LLC. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medley Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genesisbiotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Biotechnics (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations